StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
COAGBullishIndustry Newsnews
High materiality7/10

Hemab reports HMB-002 VWD data and unveils HMB-003 program at ISTH 2026

Jul 12, 2026, 7:23 AM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive early data (≥2.4x VWF/FVIII, PK/PD with monthly dosing) and the HMB-003 program may shift sentiment toward Hemab's pipeline; however, small sample size and reliance on early-stage data keep upside guarded until larger trials confirm durability and safety.

AI summary

What happened, with direct paths to the underlying reporting

Hemab presented HMB-002 data in Von Willebrand Disease showing dose-dependent increases in VWF and FVIII (≥2.4x at 150 mg) with a PK/PD profile suggesting monthly subcutaneous dosing. The company also unveiled HMB-003, a non-hormonal plasmin inhibitor with extended antifibrinolytic activity for heavy menstrual bleeding. ISTH 2026 could provide near-term momentum if early signals translate into durable clinical benefits.

  • HMB-002 in VWD shows ≥2.4x VWF and FVIII increases; PK/PD supports monthly dosing.
  • Safety profile is favorable; no serious TEAEs or thromboembolic events; no discontinuations.
  • HMB-003 announced as non-hormonal plasmin inhibitor with extended antifibrinolytic activity.
  • ISTH 2026 Paris presentations highlight HMB-002 data and HMB-003 program.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event

No related public signals are available yet.